Target Price | €51.00 |
Price | €41.90 |
Potential | 21.72% |
Number of Estimates | 23 |
23 Analysts have issued a price target Fresenius Medical Care 2026 . The average Fresenius Medical Care target price is €51.00. This is 21.72% higher than the current stock price. The highest price target is €65.10 55.37% , the lowest is €24.44 41.66% . | |
A rating was issued by 25 analysts: 9 Analysts recommend Fresenius Medical Care to buy, 12 to hold and 4 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Fresenius Medical Care stock has an average upside potential 2026 of 21.72% . Most analysts recommend the Fresenius Medical Care stock at Hold. |
24 Analysts have issued a sales forecast Fresenius Medical Care 2025 . The average Fresenius Medical Care sales estimate is €19.7b . This is 1.15% higher than the revenue of the last 12 months(TTM). The highest sales forecast is €20.9b 6.91% , the lowest is €18.7b 4.38% .
This results in the following potential growth metrics:
2024 | €19.3b | 0.61% |
---|---|---|
2025 | €19.7b | 2.10% |
2026 | €20.4b | 3.13% |
2027 | €21.3b | 4.39% |
2028 | €22.4b | 5.38% |
2029 | €23.4b | 4.48% |
2030 | €24.9b | 6.38% |
2031 | €25.2b | 1.05% |
2032 | €26.1b | 3.57% |
21 Analysts have issued an Fresenius Medical Care EBITDA forecast 2025. The average Fresenius Medical Care EBITDA estimate is €3.7b . This is 21.58% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is €4.1b 37.00% , the lowest is €2.7b 11.90% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | €3.0b | 0.73% |
---|---|---|
2025 | €3.7b | 21.57% |
2026 | €3.9b | 7.19% |
2027 | €4.1b | 4.74% |
2028 | €4.1b | 0.68% |
2029 | €4.4b | 5.30% |
2030 | €4.8b | 9.72% |
2031 | €5.0b | 5.07% |
2032 | €5.2b | 3.91% |
2024 | 15.56% | 0.12% |
---|---|---|
2025 | 18.52% | 19.04% |
2026 | 19.25% | 3.94% |
2027 | 19.32% | 0.36% |
2028 | 18.46% | 4.45% |
2029 | 18.60% | 0.76% |
2030 | 19.18% | 3.12% |
2031 | 19.95% | 4.01% |
2032 | 20.01% | 0.30% |
23 Fresenius Medical Care Analysts have issued a net profit forecast 2025. The average Fresenius Medical Care net profit estimate is €1.1b . This is 71.25% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is €1.3b 91.02% , the lowest is €1.0b 58.57% .
This results in the following potential growth metrics and future Net Margins:
2024 | €538m | 7.80% |
---|---|---|
2025 | €1.1b | 108.98% |
2026 | €1.2b | 9.64% |
2027 | €1.4b | 17.24% |
2028 | €1.6b | 11.53% |
2029 | €1.8b | 10.69% |
2030 | €2.2b | 21.57% |
2031 | €2.1b | 5.39% |
2032 | €2.2b | 7.64% |
2024 | 2.78% | 8.45% |
---|---|---|
2025 | 5.69% | 104.53% |
2026 | 6.05% | 6.33% |
2027 | 6.80% | 12.40% |
2028 | 7.20% | 5.88% |
2029 | 7.62% | 5.83% |
2030 | 8.71% | 14.30% |
2031 | 8.16% | 6.31% |
2032 | 8.48% | 3.92% |
23 Analysts have issued a Fresenius Medical Care forecast for earnings per share. The average Fresenius Medical Care EPS is €3.83 . This is 70.98% higher than earnings per share in the financial year 2024. The highest EPS forecast is €4.27 90.63% , the lowest is €3.55 58.48% .
This results in the following potential growth metrics and future valuations:
2024 | €1.83 | 7.65% |
---|---|---|
2025 | €3.83 | 109.29% |
2026 | €4.20 | 9.66% |
2027 | €4.92 | 17.14% |
2028 | €5.49 | 11.59% |
2029 | €6.08 | 10.75% |
2030 | €7.39 | 21.55% |
2031 | €6.99 | 5.41% |
2032 | €7.53 | 7.73% |
Current | 18.71 | 2.88% |
---|---|---|
2025 | 10.94 | 41.51% |
2026 | 9.98 | 8.78% |
2027 | 8.51 | 14.73% |
2028 | 7.63 | 10.34% |
2029 | 6.89 | 9.70% |
2030 | 5.67 | 17.71% |
2031 | 5.99 | 5.64% |
2032 | 5.57 | 7.01% |
Based on analysts' sales estimates for 2025, the Fresenius Medical Care stock is valued at an EV/Sales of 1.07 and an P/S ratio of 0.62 .
This results in the following potential growth metrics and future valuations:
Current | 1.08 | 1.89% |
---|---|---|
2025 | 1.07 | 1.18% |
2026 | 1.03 | 3.04% |
2027 | 0.99 | 4.21% |
2028 | 0.94 | 5.10% |
2029 | 0.90 | 4.29% |
2030 | 0.85 | 6.00% |
2031 | 0.84 | 1.04% |
2032 | 0.81 | 3.44% |
Current | 0.63 | 18.66% |
---|---|---|
2025 | 0.62 | 1.13% |
2026 | 0.60 | 3.05% |
2027 | 0.58 | 4.19% |
2028 | 0.55 | 5.11% |
2029 | 0.52 | 4.30% |
2030 | 0.49 | 5.99% |
2031 | 0.49 | 1.04% |
2032 | 0.47 | 3.45% |
Fresenius Medical Care...
Analyst | Rating | Action | Date |
---|---|---|---|
BERENBERG |
Buy
➜
Buy
|
Unchanged | Jun 30 2025 |
ODDO BHF |
Buy
➜
Buy
|
Unchanged | Jun 17 2025 |
MWB RESEARCH AG |
Hold
➜
Hold
|
Unchanged | Jun 17 2025 |
JEFFERIES |
Underperform
➜
Underperform
|
Unchanged | Jun 16 2025 |
METZLER EQUITIES |
Buy
➜
Buy
|
Unchanged | May 29 2025 |
HSBC |
Buy
➜
Buy
|
Unchanged | May 25 2025 |
DZ BANK |
Hold
➜
Buy
|
Upgrade | May 12 2025 |
Analyst Rating | Date |
---|---|
Unchanged
BERENBERG:
Buy
➜
Buy
|
Jun 30 2025 |
Unchanged
ODDO BHF:
Buy
➜
Buy
|
Jun 17 2025 |
Unchanged
MWB RESEARCH AG:
Hold
➜
Hold
|
Jun 17 2025 |
Unchanged
JEFFERIES:
Underperform
➜
Underperform
|
Jun 16 2025 |
Unchanged
METZLER EQUITIES:
Buy
➜
Buy
|
May 29 2025 |
Unchanged
HSBC:
Buy
➜
Buy
|
May 25 2025 |
Upgrade
DZ BANK:
Hold
➜
Buy
|
May 12 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.